{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:45:54Z","timestamp":1787071554752,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) patients with anti-MuSK (muscle-specific tyrosine kinase) antibody (MuSK-MG) are uncommon. Compare with MG patient with anti-ACh (acetylcholine) receptor antibody (AChR-MG), MuSK-MG exhibit unique features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The aim of this study is to analyze the difference of the clinical characteristics and electrophysiological features between MuSK-MG and AChR-MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We retrospectively review the medical records of generalized MG patients from 2004 to 2019 at Shin Kong Memorial Wu Ho-Su Hospital. We enrolled 47 MuSK-MG patients (33 females and 14 males), and 48 AChR-MG patient (23 females and 25 males).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      MuSK-MG patients have a female predominance (70.2% vs. 47.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027) and no significant difference to AChR-MG in onset age (44.02 \u00b1 15.06 vs. 47.52 \u00b1 15.85,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.273). MuSK-MG are more likely to involve facial (76.6% vs. 16.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), bulbar (100% vs. 50%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), neck (55.3% vs. 22.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), and respiratory muscles (61.7% vs. 10.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). MuSK-MG tent to experience more severe symptoms with MGFA Class III or greater (72.3% vs. 50.0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.032). The thymic pathology in MuSK-MG is likely to be normal (55.3% vs. 18.8%) or thymic hyperplasia (44.7% vs. 25%). The overall positive rate for repetitive nerve stimulation (RNS) in MuSK-MG patients is less than AChR-MG patients (66.0% vs. 85.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027). Further analysis shows the difference is mainly by recording from trapezius muscles (51.1% vs. 79.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), whereas there is no difference in nasalis muscles (60% vs. 67.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.544) and abductor digiti minimi muscles (13% vs. 18.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.582). The positive rate for single fiber electromyography (SFEMG) recording from orbicularis oculi is very high in both MuSK-MG and AChR-MG (100% vs. 97.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.289). Both MuSK-MG and AChR-MG patients achieved good outcome after proper treatment (68.1% vs. 75%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.4455).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>MuSK-MG patients have a female predominance and more facial, bulbar, neck, and respiratory muscles involvements. The electrodiagnostic features of MuSK-MG are lower positive rate of RNS at trapezius and high positive rate of SFEMG at facial muscles. Although MuSK-MG patients are associated with a more progressive course, proper diagnosis and treatment still can lead to a favorable outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ant.ant_112_0081","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:00:19Z","timestamp":1759129219000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Features and Outcome in Myasthenia Gravis Patients with Antimuscle-specific Tyrosine Kinase Antibody: A Retrospective Study"],"prefix":"10.4103","volume":"34","author":[{"given":"Yi-Chun","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Neurology, New Taipei City Hospital, New Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Horng","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan"},{"name":"Department of Neurology, College of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-Chang","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Medical University \u2013 Shuang Ho Hospital, New Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ming","family":"Lien","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan"},{"name":"Department of Neurology, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 5","key":"R2-20260420","first-page":"40S","article-title":"Seronegative myasthenia gravis","volume":"48","author":"Sanders","year":"1997","journal-title":"Neurology"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"134676","DOI":"10.1016\/j.neulet.2019.134676","article-title":"MuSk function during health and disease","volume":"716","author":"Herbst","year":"2020","journal-title":"Neurosci Lett"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"a009167","DOI":"10.1101\/cshperspect.a009167","article-title":"The role of MuSK in synapse formation and neuromuscular disease","volume":"5","author":"Burden","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","article-title":"Neuromuscular junction autoimmune disease: Muscle specific kinase antibodies and treatments for myasthenia gravis","volume":"18","author":"Vincent","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"R9-20260420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J Clin Neurol"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: An update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: Recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3988\/jcn.2017.13.3.287","article-title":"Repetitive nerve stimulation in MuSK-antibody-positive myasthenia gravis","volume":"13","author":"Kim","year":"2017","journal-title":"J Clin Neurol"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/aian.AIAN_302_19","article-title":"MuSK (muscle specific kinase) positive myasthenia: Grave prognosis or undue prejudice?","volume":"23","author":"Samal","year":"2020","journal-title":"Ann Indian Acad Neurol"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"516211","DOI":"10.3389\/fneur.2020.516211","article-title":"Regional features of MuSK antibody-positive myasthenia gravis in Northeast China","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Neurol"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"879261","DOI":"10.3389\/fneur.2022.879261","article-title":"Clinical features of myasthenia gravis with antibodies to MuSK based on age at onset: A multicenter retrospective study in China","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Neurol"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","article-title":"MuSK-antibody positive myasthenia gravis: Clinical and electrodiagnostic patterns","volume":"116","author":"Stickler","year":"2005","journal-title":"Clin Neurophysiol"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"e0193723","DOI":"10.1371\/journal.pone.0193723","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features","volume":"13","author":"Park","year":"2018","journal-title":"PLoS One"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- versus anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"R23-20260420","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.expneurol.2011.04.018","article-title":"Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice","volume":"230","author":"Punga","year":"2011","journal-title":"Exp Neurol"},{"key":"R24-20260420","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: A U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"R25-20260420","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R26-20260420","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"R27-20260420","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/mus.26107","article-title":"Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review","volume":"58","author":"Morren","year":"2018","journal-title":"Muscle Nerve"},{"key":"R28-20260420","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","article-title":"The features of myasthenia gravis with autoantibodies to MuSK","volume":"76","author":"Lavrnic","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R29-20260420","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"R30-20260420","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"R31-20260420","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1468-1331.2006.01214.x","article-title":"Seronegative myasthenia gravis: Comparison of neurophysiological picture in MuSK+ and MuSK- patients","volume":"13","author":"Padua","year":"2006","journal-title":"Eur J Neurol"},{"key":"R32-20260420","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1196\/annals.1405.005","article-title":"Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis","volume":"1132","author":"Wolfe","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R33-20260420","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1179\/1743132814Y.0000000387","article-title":"Electrophysiological profile of the patients with MuSK positive myasthenia gravis","volume":"36","author":"Nikolic","year":"2014","journal-title":"Neurol Res"},{"key":"R34-20260420","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"}],"container-title":["Acta Neurologica Taiwanica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ANT.ANT_112_0081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:48:14Z","timestamp":1787068094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ANT.ANT_112_0081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ant.ant_112_0081","relation":{},"ISSN":["1028-768X","3050-9173"],"issn-type":[{"value":"1028-768X","type":"print"},{"value":"3050-9173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2023-10-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}